Online inquiry

IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14703MR)

This product GTTS-WQ14703MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Sickle Cell Disease (SCD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14703MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2899MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ6194MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ2946MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ14385MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ4681MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ13388MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ21MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ2135MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALD-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW